Maviret

General Information

Maviret

Targeted Genotypes: 1 – 6

Treatment Description: Maviret is made up of 2 direct-acting antivirals. Glecaprevir is a NS3/4A protease inhibitor and pibrentasvir is a NS5A inhibitor.

Usage Warning: There is a risk of hepatitis B virus reactivation in patients co-infected with hepatitis C and hepatitis B viruses. Maviret should not be taken by those breastfeeding. Patients should talk to their doctor or nurse if they:

  • have severe liver injury like Child–Pugh B or C cirrhosis
  • are pregnant or are planning a pregnancy while on treatment
  • have liver problems other than hepatitis C
  • are co-infection with hepatitis B and/or HIV
  • have the rare hereditary condition of galactose (milk sugar) intolerance

Daily Dose: 3 pills
Each pill has 100 mg of glecaprevir and 40 mg of pibrentasvir in it and has to be taken with food.

Length of Treatment:

For the treatment of chronic hepatitis C genotype 1-6 in patients:# of Weeks
Genotype 1, 2, 3, 4, 5 or 6 treatment-naïve or genotype 1, 2, 4, 5, or 6 treatment-experienced with no cirrhosis8 or 12
Genotype 1, 2, 3, 4, 5 or 6 treatment-naïve or genotype 1, 2, 4, 5, or 6 treatment-experienced with cirrhosis12
Genotype 3 treatment experienced with no cirrhosis or with cirrhosis16
Treatment-experienced with DAAs*
Genotype 1 NS3/4A protease inhibitor-experienced, but NS5A inhibitor-naïve, with no cirrhosis or with cirrhosis 12
Genotype 1 NS5A inhibitor treatment-experienced, but NS3/4A inhibitor treatment-naïve, with no cirrhosis or with compensated cirrhosis16
*DAA treatment-experienced is defined as a patient who has been previously treated with DAA regimens containing daclatasvir (DCV) + SOF, DCV + PR or ledipasvir-sofosbuvir (Harvoni®), with no prior treatment experience with NS3/4A protease inhibitors, and who has relapsed or not responded to treatment OR prior treatments with NS3/4A protease inhibitors (simeprevir [SMV] +SOF or SMV + PR or boceprevir + PR or telaprevir + PR) with no prior treatment experience with NS5A inhibitors, and who has relapsed or not responded to treatment.

Common Side Effects:

  • Diarrhea
  • Headache
  • Nausea
  • Tiredness
  • Rash or itchy skin

BC’s PharmaCare Eligibility for Maviret

Maviret is a limited coverage drug. To qualify for treatment coverage a patient must be an adult who has never been treated or has been treated* and has chronic hep C genotype 1, 2, 3, 4, 5, or 6 and meets ALL of the criteria listed below OR be an adult patient who has been treated with DAAs**, has hep C genotype 1, and who also meets ALL of the following criteria:

  • Fibrosis stage of F0 or greater
  • Treatment prescribed by a hepatologist, a gastroenterologist, an infectious disease specialist or other physicians experienced with treating hepatitis C
  • Lab-confirmed hepatitis C
  • Lab-confirmed quantitative HCV RNA test from within the past 12 months
  • Not currently taking another hep C DAA treatment

*In this case, a patient who has been treated is one who has been previously treated with interferon, peginterferon-ribavirin (PR), ribavirin (RBV), and/or sofosbuvir (SOF), (PR, SOF + PR, SOF + RBV), but not with another NS3/4A protease Inhibitor or NS5A inhibitor, and who has relapsed or not responded to treatment.

**In this case, having been treated already with DAAs means a patient who has been treated with daclatasvir (DCV) + SOF or DCV + PR or Harvoni, with no prior treatment experience with NS3/4A protease inhibitors, and who has relapsed or not responded to treatment OR who was treated with older NS3/4A protease inhibitors (simeprevir [SMV] +SOF or SMV + PR or boceprevir + PR or telaprevir + PR) with no prior treatment experience with NS5A inhibitors, and who has relapsed or not responded to treatment.

Talk to your healthcare provider for more information or to start the treatment process.

AbbVie Care

Canadians prescribed Maviret can request to be enrolled in AbbVie Care. AbbVie Care supports people living with hepatitis C throughout their treatment with Maviret. The program is designed to provide a wide range of customized services including reimbursement assistance, education, and ongoing disease management support. AbbVie Care not only supports people living with hepatitis C throughout their treatment but healthcare professionals as well. For more information, contact your doctor, nurse, or call the program at:1-844-471-2273, e-mail them at maviret@abbviecare.ca, or visit maviret.abbviecare.ca.